[Congressional Record (Bound Edition), Volume 153 (2007), Part 3]
[Extensions of Remarks]
[Page 3769]
[From the U.S. Government Publishing Office, www.gpo.gov]




                       HONORING DR. EMIL FREI III

                                 ______
                                 

                            HON. DEAN HELLER

                               of nevada

                    in the house of representatives

                       Monday, February 12, 2007

  Mr. HELLER of Nevada. Madam Speaker, I rise today to pay tribute to 
Dr. Emil Frei III, a pioneer in cancer treatment, one of the world's 
foremost oncologists, and a leader in medical education.
  In addition to his many different leadership roles, throughout his 
career Dr. Frei has made notable advances in cancer treatment. His 
clinical research has made major contributions to the successful 
application of chemotherapy, a treatment method that has cured tens of 
thousands of patients. Dr. Frei served as Chief of Medicine at the 
National Cancer Institute, Associate Scientific Director Head at M.D. 
Anderson, Director and Physician-in-Chief at the Dana-Farber Cancer 
Institute, and is now the Physician-in-Chief, Emeritus, at the Dana-
Farber Cancer Institute. He has also served on the advisory or director 
boards of numerous companies and non-profit organizations, including: 
Adherex Technologies, Angstrom, CaP Cure, Celator Pharmaceuticals, DIAD 
Research, Immunogen, Infinity Pharmaceuticals, Vion Pharmaceuticals, 
Aid for Cancer Research, the Cancer Research Institute, the Journal of 
Clinical Oncology, and the New England Journal of Medicine. Dr. Frei's 
contributions have been recognized by numerous awards including the 
Lasker Award, the Kettering Prize from the General Motors Cancer 
Research Foundation, and most recently the Inaugural Lifetime 
Achievement Award from the American Association for Cancer Research.
  Not only a medical practitioner but a distinguished educator, Dr. 
Frei served as Professor of Medicine at The University of Texas for 
seven years, and at Harvard Medical School for 24 years. The textbook 
he co-authored, Cancer Medicine, was the first published about 
oncology, and remains a seminal text in this field of medicine.
  Dr. Frei is now retired in southern Nevada, but continues to lecture, 
write, and offer advice about the field in which he worked for more 
than 50 years. He now serves on the chapter board of the Southern 
Nevada Leukemia & Lymphoma Society, which will be hosting the inaugural 
Dr. Emil Frei III Symposium in March 2007.
  Madam Speaker, I am proud to pay tribute to Dr. Frei for his 
committed service to medical oncology, service that has helped 
thousands of cancer patients under his care and innumerable patients in 
the future through his leadership and instruction. His exceptional 
career deserves the highest commendation and praise.

                          ____________________